VIP Guide

VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide naturally produced in the brain, gut, and immune tissues that regulates vasodilation, immune function, circadian rhythm, and gastrointestinal motility. VIP has emerged as a key therapeutic target for chronic inflammatory response syndrome (CIRS, mold illness per Shoemaker protocol), pulmonary hypertension, and inflammatory bowel conditions. Research suggests VIP works through VPAC1/VPAC2 receptor signaling to reduce pro-inflammatory cytokine production, restore immune tolerance, and improve vascular function without immunosuppression.

What Is VIP (Vasoactive Intestinal Peptide)?

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide hormone that was first discovered in the gut but is now known to be widely distributed throughout the nervous system (especially in parasympathetic neurons), immune tissues, and endothelium. VIP is synthesized from a larger precursor protein (PACAP precursor) and is co-released with other neuropeptides and classical neurotransmitters in response to neural activity.

VIP is classified as a parasympathomimetic neuropeptide — it activates the parasympathetic ("rest and digest") nervous system and counterbalances sympathetic ("fight or flight") activation. Unlike classic parasympathetic neurotransmitters (acetylcholine), VIP has broader, slower effects mediated through two main receptor types: VPAC1 and VPAC2, which couple to Gs proteins, increase intracellular cAMP, and trigger cellular responses including vasodilation, reduced inflammation, and immune tolerance.

VIP levels naturally decline with age, chronic stress, and inflammatory diseases — suggesting VIP deficiency may contribute to age-related immune dysregulation and chronic inflammation. Restoring VIP levels is hypothesized to restore parasympathetic tone and immune homeostasis.

VIP's Multiple Physiological Roles

VIP's effects span multiple organ systems and functional domains:

• Vasodilation: VIP acts on endothelial VPAC receptors to relax vascular smooth muscle and increase blood flow. Originally named "vasoactive" for this property
• Immune regulation: VIP activates regulatory T cells (Tregs), reduces pro-inflammatory Th1/Th17 responses, and promotes immune tolerance. Decreases TNF-alpha, IL-6, IL-1 production
• Circadian rhythm: VIP is a key output signal from the suprachiasmatic nucleus (SCN, the brain's master clock), synchronizing circadian oscillations in peripheral tissues
• Gut motility: VIP stimulates intestinal smooth muscle contraction and coordinates the migrating motor complex, facilitating peristalsis and intestinal clearance
• Mucosal barrier: VIP supports intestinal epithelial tight junction integrity and promotes protective IgA production at mucosal surfaces
• Stress response: VIP is released during parasympathetic activation to counterbalance sympathetic stress responses and promote recovery

This multi-system action explains VIP's broad therapeutic potential — it's not a single-target drug but rather a master neuroimmune coordinator that restores balance across multiple dysregulated systems in chronic disease states.

VIP in Chronic Inflammatory Response Syndrome (CIRS) and Mold Illness

The most clinically advanced application of VIP therapy is in Chronic Inflammatory Response Syndrome (CIRS), a complex neuroimmune disorder triggered by exposure to biotoxins, particularly water-damaged building (mold) exposure. CIRS is also called "Mold Illness" in some contexts.

Background on CIRS: CIRS, as characterized by the Shoemaker protocol, involves inhalation of bacterial endotoxins and fungal β-glucans from water-damaged buildings, which trigger an aberrant innate immune response and fail to resolve, leading to chronic systemic inflammation. Key features include:

• Elevated pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1, IL-17)
• Abnormal visual contrast sensitivity (VCS) testing
• Elevated complement activation (C4a, TGF-beta)
• Immune dysregulation (reduced regulatory T cells, Th17 skewing)
• Multi-system symptoms: neuroinflammation, fibromyalgia-like pain, dyspnea, orthostatic intolerance

VIP's role in CIRS: The Shoemaker protocol identifies VIP deficiency as a central feature of CIRS. VIP activates VPAC receptors on Tregs and other immune cells, promoting anti-inflammatory IL-10 and TGF-beta production while suppressing pro-inflammatory TNF-alpha and IL-17. By restoring VIP signaling, the protocol aims to restore immune tolerance and resolve the chronic inflammatory cascade. Studies using VIP in CIRS patients show improvements in neuroinflammatory symptoms, normalization of inflammatory biomarkers, and clinical symptom resolution.

Dosing in CIRS protocols: The Shoemaker CIRS protocol typically uses intranasal VIP 50 mcg twice daily (morning and evening). This dosing was derived from clinical experience and has become standard in CIRS treatment centers. Protocols last 12–24 months typically, with dose adjustments based on symptom response and biomarker normalization.

VIP for Pulmonary Hypertension and Vascular Function

VIP is also a potent vasodilator and is being researched for pulmonary hypertension (elevated blood pressure in the pulmonary circulation), a serious condition affecting the right heart.

Mechanism in pulmonary hypertension: Pulmonary hypertension involves vasoconstriction, endothelial dysfunction, and excessive proliferation of pulmonary vascular smooth muscle. VIP acts on VPAC receptors on vascular endothelium and smooth muscle to: (1) directly relax smooth muscle via cAMP activation, (2) inhibit smooth muscle proliferation, (3) reduce endothelial-derived vasoconstrictor tone, and (4) suppress pro-inflammatory cytokines driving vascular inflammation.

Clinical research: Studies in pulmonary hypertension models show VIP improves pulmonary vascular hemodynamics, reduces right ventricular strain, and improves exercise tolerance. A synthetic VIP analog, aviptadil, was in development for treatment of pulmonary hypertension and shown benefit in Phase 2 trials. While full VIP therapy for pulmonary hypertension remains investigational, the mechanistic basis is compelling.

Broader vascular applications: VIP's vasodilatory and anti-inflammatory properties suggest utility in systemic hypertension, endothelial dysfunction, and ischemic tissue protection — though clinical translation remains limited.

VIP for Inflammatory Bowel Disease and Gut Healing

The gut is a major site of VIP synthesis and action. Intrinsic neurons of the enteric nervous system release VIP to regulate motility, secretion, and immune function. In inflammatory bowel disease (Crohn's disease and ulcerative colitis), VIP signaling is often dysregulated.

Mechanism in IBD: VIP activates VPAC receptors on intestinal epithelial cells, immune cells, and enteric neurons. This triggers: (1) IL-10 production from immune cells (anti-inflammatory), (2) reduced TNF-alpha and IL-6 production, (3) improved epithelial tight junction integrity, (4) enhanced protective IgA production at mucosal surfaces, and (5) restored intestinal motility and gut barrier function.

Animal model evidence: VIP administration in colitis models reduces inflammation scores, decreases pro-inflammatory cytokine production, restores barrier integrity, and accelerates healing. VIP's dual mechanism (immune modulation + barrier support + motility restoration) makes it mechanistically attractive for IBD.

Human clinical data: Limited human trials exist, but case reports and small series suggest VIP therapy improves IBD symptoms, reduces inflammatory markers, and may induce disease remission. More rigorous clinical trials are needed, but mechanistic plausibility is high.

VIP and Circadian Rhythm Restoration

VIP is a master circadian synchronizer. The suprachiasmatic nucleus (SCN) in the hypothalamus is the brain's master clock, and VIP is a key output signal that synchronizes circadian oscillations in the rest of the brain and body. Light exposure triggers VIP release from the SCN, which resets peripheral circadian clocks in organs and tissues.

In chronic illness: Chronic stress, inflammation, and systemic disease often disrupt circadian rhythm — manifest as sleep disruption, altered hormone secretion, and loss of daily immune cycling. This circadian disruption perpetuates inflammation and impairs recovery. VIP administration, particularly with intranasal delivery (which achieves rapid CNS penetration), may help restore circadian synchronization and improve sleep-wake cycles.

Practical implications: VIP therapy in chronic inflammatory conditions like CIRS may improve sleep quality and circadian-dependent immune function, contributing to overall recovery.

VIP Dosage and Administration Routes

Standard CIRS protocol: The Shoemaker protocol uses intranasal VIP 50 mcg twice daily (e.g., 8 AM and 8 PM). This dosing is based on clinical experience with CIRS and mold illness. Treatment duration is typically 12–24 months, with dose adjustments based on symptom response and biomarker normalization (C4a, VCS testing, etc.).

Intranasal advantage: Intranasal delivery offers rapid onset (minutes to hours), excellent CNS penetration (direct to olfactory epithelium and cranial nerves), and avoidance of gastric degradation. This is why intranasal VIP is preferred for CIRS and neuroinflammatory conditions.

Onset of action: VIP effects typically begin within days to weeks. Some patients report improved symptoms (reduced brain fog, improved sleep) within the first week of intranasal VIP. Full immune recalibration and resolution of biomarkers (C4a normalization) may take 3–6 months.

VIP and the Shoemaker Protocol for Mold Illness

Complete CIRS treatment includes: The Shoemaker protocol is multifaceted and typically includes: (1) biotoxin avoidance (leaving the water-damaged environment), (2) cholestyramine or other biotoxin binders, (3) VIP intranasal therapy, (4) treatment of concurrent infections or comorbidities, (5) monitoring with VCS testing and serum biomarkers (C4a, TGF-beta), and (6) functional restoration (physical therapy, graded exercise).

VIP's role: VIP addresses the immune dysregulation at the heart of CIRS — restoring immune tolerance, reducing pro-inflammatory cytokine production, and synchronizing parasympathetic recovery. Combined with biotoxin avoidance and other interventions, VIP is reported to help achieve clinical remission of CIRS.

Evidence base: The Shoemaker protocol and VIP therapy in CIRS are supported by observational data and case series but lack large randomized controlled trials. The mechanistic basis is strong, and clinical reports of improvement are frequent, but more rigorous clinical trials would strengthen the evidence base.

Side Effects and Safety Profile

VIP has a favorable safety profile when used at therapeutic doses via intranasal or other routes.

Common observations: Intranasal VIP is generally well-tolerated. Mild nasal irritation, transient headache, or increased energy/wakefulness (due to parasympathomimetic activation) are the most common observations. Most side effects are mild and transient or resolve as the body acclimates.

Theoretical concerns at high doses: Excessive parasympathomimetic stimulation could theoretically cause excess vasodilation, hypotension, or GI effects (diarrhea from increased gut motility). However, at standard CIRS dosing (50 mcg intranasal 2x daily), systemic effects are minimal.

Contraindications: VIP should be used cautiously in severe hypotension, acute vasodilatory crisis, or uncontrolled hypersensitivity. Pregnancy safety data is limited; conservative approach is to avoid in pregnancy.

Drug interactions: Minimal interactions expected at standard doses. VIP's mechanism (cAMP elevation) is distinct from major drug classes, so interactions are unlikely. However, use with other parasympathomimetics (acetylcholinesterase inhibitors) should be monitored for additive effects.

VIP Receptor Biology and Mechanism

VIP's effects are mediated through two main receptor subtypes: VPAC1 and VPAC2, both coupled to Gs proteins and adenylyl cyclase. Activation triggers increased intracellular cAMP, which activates protein kinase A (PKA) and other downstream signaling pathways leading to:

• Vascular effects: Relaxation of vascular smooth muscle, vasodilation, improved blood flow
• Immune effects: Activation of regulatory T cells (Tregs), increased IL-10 and TGF-beta production, suppression of Th1/Th17 responses
• Neuronal effects: Neuroprotection, synaptic plasticity, neurotrophic factor expression
• Epithelial effects: Tight junction stabilization, mucosal barrier support, IgA production

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions